- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 103,100 | 24.09.24 15:10:53 | -0,640 | -0,62% | 102,920 | 103,000 | 103,580 | 103,740 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 979,000 | 24.09.24 15:02:04 | -5,200 | -0,53% | 943,800 | 951,600 | 976,200 | 984,200 |
